Polyvalent AIDS Vaccines

Strategies for AIDS vaccines.

In the global AIDS epidemic, over half of all infections have occurred in people less than 25 years old resulting in profound social, economic and demographic consequences. Current estimates indicate that the present 15 million HIV infections will increase to over 30 million by the end of the millennium. For most countries a safe and effective vaccine offers the only hope of controlling the spr...

Post-vaccination reactions in donkeys vaccinated with African Horse Sickness polyvalent vaccines

Attenuated retrovirus vaccines and AIDS.

(1995). outlined by K. Sheehan et al. [J. Immunol. 142, 3884 splenocytes by culture with MulL-12 (10 U/ml Hoff4. S. Hemmi, R. Bohni, G. Stark, Cell 76, 803 (1994); J. (1989)]. 1 G5, 1 Fl, and 2E2 are hamster mAbs spemann-La Roche, Nutley, NJ) and MuIL-4 mAb Soh et a/., ibid., p. 793; S. A. Marsters, D. Pennica, E. cific for the MuIFN-y receptor (x chain. The MuIFN--y (1 1 B1 1) (10 ,ug/ml, DNAX...

DNA/MVA Vaccines for HIV/AIDS

Since the initial proof-of-concept studies examining the ability of antigen-encoded plasmid DNA to serve as an immunogen, DNA vaccines have evolved as a clinically safe and effective platform for priming HIV-specific cellular and humoral responses in heterologous "prime-boost" vaccination regimens. Direct injection of plasmid DNA into the muscle induces T- and B-cell responses against foreign a...

AIDS vaccines: money games and elusive strategies.

Vol 32 No. 1 March 2001 1 HIV/AIDS arguably is the most insidious plague of current times. This field has had more research money thrown at it in a short time than any other disease group in history: we are entitled, then, to question the outcome globally in terms of cost effectiveness. The difficulty in so doing lies with uncertainties of both the science and the economics. Both public and pri...